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Abstract: Background: Neonatal Jaundice secondary to isoimmune haemolytic anemia (Rh and ABO
incompatibility) is a cause of high serum bilirubin level due to haemolysis of red blood cells secondary
to transplacental passage of antibodies. Intravenous immunoglobulins (IVIG) have been successfully used
in isoimmune hemolytic jaundice and were found to decrease hemolysis leading to reduction in serum
bilirubin level and subsequently decreasing the need for exchange transfusion. Patients and methods: This
study was conducted on 30 full term neonates with isoimmune-hemolytic jaundice admitted in the neonatal
intensive care units in New Children's hospital, Cairo University. They were randomly classified into 2
groups Group I: "Study group” (15) neonates presented with isoimmune hemolytic jaundice treated by
phototherapy + single dose of I.V immunoglobulin infusion (0.5 gm/Kg). Group II: "Control group” (15)
neonates presented with isoimmune-hemolytic jaundice treated by phototherapy only. Results: the rate of
decrement in total serum bilirubin (TSB) was significant in the study group compared with the control
group 24 and 48 hours after therapy where the P value was 0.000 and 0.001 respectively. The number
of patients who required exchange transfusion was significantly lower in the study group than in the
control group (P=0.007). Conclusion: intravenous immunoglobulins (IVIG) have been successfully used
in newborns with isoimmune hemolytic jaundice. Routine use of Intravenous immunoglobulin therapy in
treatment of isoimmune hemolytic jaundice plus conventional Phototherapy is recommended to decrease
the need for exchange transfusion and avoid its complications. 
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INTRODUCTION
Neonatal Jaundice is one of the commonly seen
neonatal problems, as it affects 60% of full term
infants and 80% of preterm infants in the first 3 days
of life .[1]
Neonatal Jaundice secondary to isoimmune
haemolytic anemia (Rh and ABO incompatibility) is a
cause of high serum bilirubin level due to haemolysis
of red blood cells secondary to transplacental passage
of antibodies. This leads to increased risk of bilirubin
encephalopathy and kernicterus at bilirubin levels lower
th a n  th a t  o f  j aund ic e d  n e w b o r n s  w i th o u t
isoimmunisation or active haemolysis .[2]
Regardless of the etiology, the goal of therapy is
to lower the concentration of circulating bilirubin or
keep it from increasing and reaching the levels at
which neurotoxicity may occur .[3]
The conventional treatment measures for neonatal
immune hemolytic disease are Phototherapy and blood
exchange.  Phototherapy, converts bilirubin to products
that can bypass the conjugating system and be excreted
in the bile or the urine without further metabolism [3 ,4]
Exchange transfusion removes bilirubin mechanically
and is sometimes needed beside phototherapy as it
corrects anemia associated with hemolysis and is
effective in removing sensitised red blood cells before
they are hemolysed. It also removes about 60% of
bilirubin from the plasma.  Exchange transfusion
carries 5%risk of major morbidities including
in fe c t io n s ,  a p n e a ,  p u l m o n a r y  h e m o r r h a g e ,
thrombocytopenia, coagulopathies, hypoglycemia,
hypocalcaemia, electrolyte imbalance, vasospasm,
thrombosis, hypertension, arrhythmias, and necrotizing
enterocolitis .[5 ,6 ,7]
In isoimmune hemolytic diseases of the newborn,
(Rh-ABO incompatibility), antibodies (Anti-A, anti-B,
anti- D) coated erythrocytes are mainly eliminated
through, antibody dependant cellular cytotoxic effect by
Fc receptor bearing cells of the reticuloendothelial
system .[8]
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Intravenous immunoglobulins (IVIG) have been
successfully used in isoimmune haemolytic anemia
(Rh-ABO incompatibility); as its administration is a
less complicated  as  wel l as  less  invasive
therapy . Intravenous Immunoglobulins were[9 ,10 ,11 ,12 ,13 ,14]
found to decrease hemolysis leading to reduction in
serum bilirubin level. The exact mechanism of action
of IVIG in hemolytic disease of the newborn is still
unknown. The immunoglobulin could act by occupying
the FC receptors of reticulo -endothelial cells
preventing them from taking up and lysing antibody
coated RBCs. This subsequently leads to decrease in 
the need for exchange transfusion . Undesirable[13 ,15 ,16]
effects from IVIG occur in less than 5% of patients
and include headache, flushing, chills, wheezing,
tachycardia, low back pain, nausea and hypotension. If
this happens during infusion, the infusion should be
slowed or stopped; if symptoms are anticipated, the
patient can be premedicated with antihistamines and
intravenous hydrocortisone .[17]
PATIENTS AND METHODS
Patients: This study was conducted on 30 neonates
with isoimmune-hemolytic jaundice admitted in the
neonatal intensive care units in New Children's
hospital, Cairo University. They were randomly
classified into 2 groups:
Group I: "Study group” (15) neonates presented with
isoimmune hemolytic jaundice treated by phototherapy
+ single dose of I.V immunoglobulin infusion (0.5
gm/Kg).
Group II: "Control group” (15) neonates presented
with isoimmune-hemolytic jaundice treated by
phototherapy only.
Both groups were compared with each other
regarding the rate of decrement in serum bilirubin,
duration of phototherapy and number of babies required
exchange transfusion.
Term neonates ($ 37 weeks gestational age) with
isoimmune hemolytic jaundice due to Rh or ABO
incompatibility between blood group of the mother and
the baby ,proved by Positive direct Coomb’s test and
clinical jaundice in the first 36 hours of life were
included in the study.
Significant hyperbilirubinemia; was defined as
hyperbilirubinemia requiring phototherapy and/or rising
by (0.5mg/dl per h) or if the total serum bilirubin level
exceed (10 mg/dl), (12 mg/dl), (14 mg/dl) at <12hr,
<18hr or <24hr of the infant age respectively .[18]
Preterm neonates, neonates with infections,
hematomas, gastrointestinal abnormalities as well as
pathological conditions other than isoimmune
haemolytic jaundice e.g. (respiratory distress syndrome
and intrauterine growth retardation) were excluded from
the study.
All the studied cases (Group I and Group II) were
subjected to the following:
(A) Clinical Evaluation:
1-History taking (complete obstetric and medical
history of the mother stressing on prenatal, natal, and
postnatal history)
2 -Thorough clinical examination including:
General examination: (vital signs, birth trauma, neonatal
reflexes, and congenital anomalies).
Systemic examination : (cardiac, abdominal, chest and
neurological examination, 
B) Phototherapy: each neonate was placed naked
body, covering the eyes and genitalia, at distance of
30-40 cm from the light source in an incubator and
was managed with continuous phototherapy.
(C) Laboratory Investigations: serum bilirubin level
(total and direct), direct coomb's test, reticulocytic
count and complete blood count.
Intravenous Immunoglobulin: The neonates were
treated by 0.5 gm/kg single dose of I.V-Globulin S
(Heat-treated Immune Serum Globulin) at the time of
admission through intravenous (I.V) infusion over 4
hours at a rate of 0.01mg/kg/minute (for group I
only) . Estimation of serum bilirubin was done after[17]
4 hours from termination of infusion and then every 24
hours. No adverse reactions have been observed in the
studied patients.
Statistical Analysis: SPSS program (version 12) was
used in the statistical presentation and analysis of the
present study using the mean, standard error, unpaired
student t-test, chi-square test and the Mann-Whitney
test. 
RESULTS
In this work thirty neonates suffered from neonatal
jaundice due to Rh or ABO incompatibility were
studied; they were divided into two groups. Group I
(treated group or the study group) and Group II
(control group or the non treated group).
The general characteristics and laboratory data of
both groups are presented in (Table 1) and showed no
significant statistical difference between them (p>0.05).
These characteristics included the gestational age
(weeks), birth weight (grams), type of isoimmunization
(Rh or ABO), family history of neonatal jaundice,
onset of jaundice (days) and age of admission (hours).
In each  group  14 patients had ABO incompatibility;
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Table 1: General characteristics and laboratory data of both groups.
Group I Group II t-test P value
Gestational age (Weeks) 37.93±0.961 37.8±0.775 0.42 0.68
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Birth weight  (grams) 3040±324.7 3033.33±330.94 0.056 0.95
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Family history with other child with jaundice 6 (40%) 4 (26.67%) 0.35
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Onset of jaundice (days) 1.27±0.46 1.4±0.5 - 0.76 0.46
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Age of admission (hours) 35.13±20.9 37.93±22.2 - 0.36 0.72
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
HB level (g/dl) 12.1±1.45 12.22±2.25 - 0.16 0.87
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Reticulocytic count 11.04±4.75 10.19±8.3 0.35 0.73
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Hematocrite percent 36.5±4.98 34.96±6.48 0.73 0.47
Table 2: Total serum bilirubin (TSB) in Group I and Group II 24 hours and 48 hours from therapy.
TSB(mg/dl) Group I Group II t- test P value
On admission  13.6-31.1 14.00-30.90
--------------------------------------------------------------------------------------------------------------------
18.747±4.474 21.458±5.346 -1.506 0.143
24 hours 10.80-25.00 15.12-29.90
--------------------------------------------------------------------------------------------------------------------
15.833±3.736 22.527±4.380 -4.503 0.000*
48 hours 6.70-29.10 15.70-30.00
--------------------------------------------------------------------------------------------------------------------
13.120±5.293 18.879±3.409 -3.543 0.001* 
*P>0.001 is highly significant .
Table 3: The change in Total Serum Bilirubin (TSB) in both groups 24 hours and 48 hours after therapy as compared with the initial value
on admission.
Group  TSB t- test P-value 






15.833 ± 3.736 3.314 0.005*
-----------------------------------------------------------------------------------------------------------------------
After 48h. 6.70- 29.10
-----------------------------------------------------------------------------------------------------------------------
13.120±5.293 4.560 0.000*
Group II On Admission 14.00-30.90
-----------------------------------------------------------------------------------------------------------------------








18.879 ±3.409 3.144 0.007*
* P>0.05 is significant .
* P>0.001 is highly significant.




Group I N 14 1 15
---------------------------------------------------------------------------------------------------------------------------------------------------
% 93.33 6.67 100.00
Group II N 7 8 15
---------------------------------------------------------------------------------------------------------------------------------------------------
% 46.67 53.33 100.00
Total N 21 9 30
---------------------------------------------------------------------------------------------------------------------------------------------------
% 70.00 30.00 100.00
Fisher's exact test 0.007
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Fig. 1: Rate of Decrement in Total Serum Bilirubin in Both Groups 24 Hours and 48 Hours after Therapy.
Fig. 2: Frequency of Exchange Transfusion in Both Groups.
Rh+ ABO was present in 1 patient in each group and
none of the patients had Rh incompatibility alone in
both groups. The laboratory data included the
hemoglobin (HB) level (g/dl), Reticulocytic count and
hematocrite (Hct %) percent and showed no significant
statistical difference between (Group I) and (Group
II) (p>0.05). 
The rate of decrement in the total Serum Bilirubin
(TSB) in Both Groups 24 Hours and 48 Hours after
Therapy is presented in (table 2 and fig.1) which show
that There was no significant statistical difference
between (Group I )and (Group II) in (TSB) level on
admission(p>0.05); while after24 and 48 hours of
therapy the (TSB) level was significantly lower in the
treated group (Group I) than the control group (Group
II) where the p value was 0.000 and 0.001
respectively.(Table 3) displays the change in (TSB) in
Both Groups 24 Hours and 48 Hours after Therapy as
compared with the initial value on admission and
shows that there was significant statistical difference
between (TSB) after 24 hours and 48 hours in (Group
I)(p=0.005 and 0.000 respectively) and a significant
statistical difference in (TSB) after 48 hours only in
(Group II)(p=0.007).
Regarding the duration of phototherapy the
difference was not statistically significant (p>0.05) in
both groups where in the patient group the mean
duration was (85.07±24.33 hours) and in the control
group the mean duration was (96.33±20.48 hours).
(Table 4 and fig.2) present the frequency of
exchange transfusion in both groups where the number
of patients who required exchange transfusion was
significantly higher in the control group (Group II)
than in the study or treated   group (Group I)
(p=0.007).
DISCUSSION 
Hemolytic jaundice caused by blood group
incompatibility has significant morbidity and mortality
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in neonatal period. It is accepted that introduction of
anti-D for prophylaxis of Rh incompatibility reduces
the number of cases with hemolysis. However, because
the prophylactic anti-D treatment cannot often be given
in time or in adequate dosage, Rh hemolytic disease
remains an important problem of neonates, furthermore,
there is no prophylactic treatment for ABO or Rh
subgroup incompatibilities. The conventional therapy
for this disease is phototherapy, hydration and
exchange transfusion. (13)
Intravenous immunoglobulin (IVIG) therapy is now
used in the treatment of Hemolytic disease of the
newborn (HDN). They reduce the need for exchange
transfusion, duration of  hospita lization, and
phototherapy. (12 , 13)
In our experience we studied the effect of a single
dose of IVIG therapy (500mg/kg) on neonates with
isoimmune hemolytic jaundice; which was in
concordance with other studies  in which the(14 , 19)
effect of a single dose of IVIG (500 mg/kg) on term
and preterm neonates was examined. In other
reports  different dose regimens of IVIG (1g/kg[20 ,21 ,22]
and 800mg/kg) were also tried in neonates with
isoimmune hyperbilirubinaemia. Some authors
systematically reviewed the effect of intravenous
immunoglobulins in hemolytic disease of the newborn,
comparing four controlled trials on 226 neonates and
all the studies included showed a beneficial effect,
despite the variation in IVIG doses. They suggested
that a single dose of 500 mg/kg is as effective as any
other treatment regimen .[13]
Agreeing with other results  we found no[12 ,14]
significant statistical difference between both groups
concerning gestational age, birth weight; as well as the
hemoglobin level, reticulocytic count and the initial
level of serum bilirubin.
In accordance with other studies  we proved that[9 ,23]
there was a highly Significant decrease in the number
of cases who needed exchange transfusion in the group
treated with IVIG (15 patients) where only one of them
(6.67%) required exchange transfusion in view of 7
cases (46.67%) of the control group (15 patients) who
were  in  need  for   exchange  transfusion.  (p<o.o1)
Supporting our findings, many authors  studied[9 ,14 ,19]
the effect of a single dose IVIG (500mg/kg) on
neonates with significant hyperbilirubinaemia due to
ABO and Rh hemolytic disease and their results
showed a significant decrease in the number of cases
in need for exchange transfusion in the treated group
compared with the control group where the P value
was <0.005, <0.01 and <0.05 respectively. Previous
studies  examined the effect of multiple doses (500[12]
mg/kg) IVIG therapy during 3 consecutive days versus
single dose (500 mg/kg) IVIG therapy on neonates with
isoimmune hemolytic hyperbilirubinemia The rate of
exchange transfusion in multiple doses IVIG treated
group, was lower than the single dose IVIG treated
group (P<0.01).Also the rate of exchange transfusion in
the single dose IVIG treated group was lower than the
control group babies who didn't receive any IVIG
(P<0.05).
In keeping with other reports ; our experience[9 ,1 9 ]
showed  no  statistically  significant  difference in the
duration of phototherapy in the treated group (mean
85.067±24.33hours) compared with the control group
babies who had only phototherapy (mean 96.33_+20.48
hours). (P>0.05)
We reported no immediate adverse effects related
to IVIG including fever, allergic reactions, volume
overload or hemolysis, which agreed with the findings
observed by many authors who detected no immediate
adverse effects related to IVIG .[11 ,12 ,14 ,19 ,21 ,22]
In conclusion intravenous immunoglobulins (IVIG)
have been successfully used in newborns with
isoimmune hemolytic jaundice; our results showed
significant decrease in the number of cases in need for
exchange transfusion, in the treated group more than
the control group (P value < 0.01). Routine use of
Intravenous immunoglobulin therapy in treatment of
isoimmune hemolytic jaundice plus conventional
Phototherapy is recommended to decrease the need for
exchange transfusion and avoid its complications.
Further studies are also needed to determine the best
regimen in Intravenous immunoglobulin therapy, single
dose versus multiple doses, the dose itself and the best
time for initiation of therapy.
REFERENCES
1. Bhat, S., 2005. Neonatal Jaundice. In: Guha D K
(eds). Guha’s Neonatology Principles and Practice,
3rd edition. Jitender P vij, (2): 882-888.
2. Borgard, J., P. Szymanaowica, V. Szmidt-Adjide,
2006. '' Determination of the Total bilirubin level
in Whole Rota M blood from neonates" Clin chem
lab Med., 44(9): 1103-10.
3. Maisels, M., F. Antony, McDonagh, 2008.
Phototherapy for Neonatal Jaundice. Clinical
therapeutics, 358: 920-928.
4 Siberry, G., R. Lannone, 2000. Criteria for
exchange transfusion in jaundiced newborn. In:
Hoffman HJ, Bryla DA, Schedit PC (eds). The
Harriet Lane handbook: Manual for pediatric.
House officers. Mosby-year book inc, 15(4): 257-8.
5 Newman, T., B. Xiong, V. Gonzales, G. Escobar,
2000. Prediction and prevention of extreme
neonatal hyperbilirubinemia in a mature health
maintenance organization  Arch Pediatr Adolesc
Med. 2000 Nov., 154(11): 1140-7. 
J. App. Sci. Res., 5(11): 1923-1928, 2009
1928
6 Koeing, M., R. Christensen, 2000. Evaluation and
treatment of Erythroblastosis fetalis in neonate In:
Christensen RD (ed.), Hematologic problem of the
neonate. Saunders company, 16(4): 169 -174.
7 Koeing, M., 2000. Evaluation and treatment of
Erythroblastosis fetalis in neonate. In: Christensen
R, ed. Hematologic problems of the neonate. 1st
ed. Philadelphia, Pa: WB Saunders, 185-207.
8 Garratty, G., S.A. Glynn, R. McEntire, 2004. ABO
and Rh(D) Phenotype frequencies of different
racial/ethnic groups in the United states
.Transfusion, 44(5): 703-6.
9 Rübo, J., K. Albrecht, P. Lasch, et al., 1992. High
dose Intravenous immune globulin therapy for
neonatal hyperbilirubinemia caused by Rh
hemolytic disease. J pediatr; Jul., 121(1): 93-7.
10 Sato, K., T. Hara,  T. Kondo,  H. Iwao,  S.
Honda,  K. Ueda, 1991. High dose Intravenous
gammaglobulin therapy for neonatal immune
haemolytic jaundice due to blood group
incompatibility. Acta Paediatr Scand; Feb., 80(2):
163-6.
11 Ergaz, Z. and I. Arad, 1993. Intravenous
immunoglobulin therapy in neonatal hemolytic
jaundice.  J Perinatr Med., 21(3): 183-7.  
12 Tanyer, G.,  Z. Siklar,  Y. Dallar,  Y. Yildirmak,
U. Tiras, 2001. Multiple Dose IVIG Treatment in
Neonatal Immune Hemolytic Jaundice. Journal of
Tropical Pediatrics, 47(1): 50-3.
13 Gottstein, R., R.W.I. Cook, 2003. Systematic
review of intravenous immunoglobulin in
haemolytic disease of the newborn. Arch Dis Child
Fetal Neonatal Ed. 2003 Jan., 88(1): F6-10.
14 Miqdad, A.M., O.B. Abdelbasit, M.M. Shaheed,
M.Z. Seidahmed,, A.M. Abomelha, O.P. Arcala,
2004. Intravenous immunoglobulin G (IVIG)
therapy for significant Hyperbilirubinemia in ABO
hemolytic disease of the newborn. J Matern Fetal
Neonatal Med. 2004 Sep., 16(3): 163-6. 
15 Mundy, C.A., 2005. Intravenous immunoglobulin
in management of haemolytic disease of the
newborn. Neonatal Netw. 2005 Nov-Dec., 24(6):
17-24. Review. 
16 Dalakas, M.C., 2002. Mechanisms of action of
IVIG and therapeutic considerations in the
treatment of acute and chronic demyelinating
neuropathies. Neurology. 2002 Dec., 59(12 Suppl
6): S13-21.
17 Cant, A., D. Gibb, E. Davies, et al., 2003.
:Replacement therapy in immune deficiency in
Forfar and Arnei's text book of pediatrics 6th ed
edited by Niel McIntosh, peter Helms, Rosalind
smyth, pp: 1293. Churchll Livingstone.
18 Hansen, T., 2002. Therapeutic approaches to
neonatal jaundice: an international survey. Clin
Pediatr (Phila). 1996 Jun, 35(6): 309-16.
19 Mukhopadhyay, K., S. Murki A. Narang, Dutta S.,
2003. Intravenous Immunoglobulins in Rhesus
Hemolytic Disease. Indian J Pediatr, 2003 Sep.,
70(9): 697-9.
20 Walsh, S.A., N. Yao, A. El-Khuffash, A. Twomey,
E.J. Molloy, 2008. Efficacy of Intravenous
Immunoglobulin in the Management of Haemolytic
Disease of the Newborn. Ir Med J. Feb., 101(2):
46-8.
21 Alpay, F., S.U. Sarici, V. Okutan, G. Erdem, O.
Ozcan, E. Gökçay, 1999. High dose Intravenous
immunoglobulin therapy in neonatal immune
haemolytic jaundice. Acta Paediatr.  Feb., 88(2):
216-9. 
22 Voto, L.S., H. Sexer, G. Ferreiro, J. Tavosnanska,
J. Orti, E.R. Mathet, M. Margulies, M. Margulies,
1995. Neonatal administration of High dose
Intravenous immunoglobulin in rhesus hemolytic
disease. J Perinat Med., 23(6): 443-51.
23 Kutukculer, N., N. Kulturasay, N. Tansug, et al.,
1995. High dose intravenous immunoglobulin
therapy for neonatal hyperbilirubinemia caused by
Rh hemolytic and ABO hemolytic disease. Med J
Ege Univ, 5: 29-31.
